All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BCG vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Vaccine
Partner/Sponsor/Collaborator: Hellenic Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
BCG-vaccinated participants had their first infection on average 16 weeks after vaccination, compared to 11 weeks for the placebo group. There was no difference in side effects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rabies Immune Globulin [Human]
Therapeutic Area: Infections and Infectious Diseases Product Name: Kedrab
Highest Development Status: Phase IV Product Type: Vaccine
Partner/Sponsor/Collaborator: Kedrion
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eicosapentaenoic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Vascepa
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
MITIGATE COVID-19 will randomly assign 1500 U.S. patients aged 50 years or older with established ASCVD and no prior history of confirmed COVID-19 to receive 4 grams per day of icosapent ethyl (VASCEPA) and follow these patients for a minimum of 6 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zingivir-H
Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H
Highest Development Status: Phase IV Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
The studies found that 58 patients treated with the herbo-mineral drug, ZingiVir-H recovered and reported a negative Reverse Transcription Polymerase Chain Reaction (RT-PCR) recovery in an average of five days while others took an average of eight days to recover.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amrta Karuna
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Notable results for the Amrta Karuna treatment group compared to the control showed Significant reduction in hospital quarantine (28% decrease) , Significantly reduced CRP inflammatory levels, RT-PCR negative on day 7 at 71.42% vs 42.85% , TLC within normal range.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Immune Globulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: FabiFlu
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team within the country, ensuring self-reliance with regard to longterm production and manufacturing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zingivir-H
Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H
Highest Development Status: Phase IV Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2020
Details:
Clinical trials of ZingiVir-H, Pankajakasthuri’s new drug, are underway among 112 patients as an adjunct therapy for the pandemic as well as among 135 additional patients as a stand-alone treatment in a double-blind study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eritoran
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: The Global Coalition for Adaptive Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 01, 2020
Details:
The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DMX-200
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global the REMAP-CAP program aimed at treating patients with Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
